You are invited to take a look at the draft Framework for Consumer Engagement in Heath Technology Assessment (HTA)and share your feedback directly with the government.
Over the past couple of years, you – the Australian Myasthenia Gravis patient community – have contributed to the HTA process for new and innovative treatments being made available through our Pharmaceutical Benefits Scheme (PBS). Our experiences including challenges or barriers with this process are valuable for the Department of Health as they work to strengthen consumer engagement in HTA.
The Department’s Consumer Evidence and Engagement Unit are dedicated to working with consumers as partners and ensuring that the patient voice is a key part of the decision-making process. Consumer engagement in the HTA process should be consistent, clear, and meaningful. This is your chance to help inform, and improve, the bigger picture for all patients and consumers!
The Framework is a short 3-page document that explains how consumer (patient) engagement happens across HTA processes in Australia. It sets out guiding principles, focus areas, and actions to support better consumer engagement in HTA.
To view the framework and read more, please click here.
The survey is open until Tuesday 26 May 2026 and you can complete it online here.
If you have difficulty responding online, please email htaconsumerengagement@health.gov.au
Please note that this survey is not run by the MAA, but we encourage you to share your feedback with government if you would like to, especially if you recently made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) for new MG treatments.
